The risk assessment of CBC and the benefit of CRRM in BRCA1 and BRCA2 P/LP variant carriers should consider age at diagnosis, family history of breast cancer, the overall prognosis from the first breast cancer or other cancers, the ability of the patient to undergo proper breast surveillance, comorbidities, and life expectancy [151]. This evidence concerns the gene BRCA2 and breast cancer.